TY  - JOUR
AU  - Slamon, D J
AU  - Neven, P
AU  - Chia, S
AU  - Jerusalem, G
AU  - De Laurentiis, M
AU  - Im, S
AU  - Petrakova, K
AU  - Valeria Bianchi, G
AU  - Martín, M
AU  - Nusch, A
AU  - Sonke, G S
AU  - De la Cruz-Merino, L
AU  - Beck, J T
AU  - Ji, Y
AU  - Wang, C
AU  - Deore, U
AU  - Chakravartty, A
AU  - Zarate, J P
AU  - Taran, T
AU  - Fasching, P A
PY  - 2021
DO  - 10.1016/j.annonc.2021.07.011
UR  - https://hdl.handle.net/10668/27558
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
LA  - en
TI  - Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024].
TY  - research article
VL  - 32
ER  -